Is Bristol Myers Squibb a Good Stock to Buy?

Bristol Myers Squibb Co. (NYSE:BMY) is down 5% so far this year, as the company saw bad news break in early August when it suspended a trial for its prospective drug for treating hepatitis C following safety concerns. This followed Bristol Myers Squibb’s report that in the second quarter of 2012 its sales were down 18% versus the same period a year ago, reversing the increase in revenue it had experienced in the first quarter. The same pattern applied to net income: last quarter, earnings attributable to the company (income from noncontrolling interests was particularly high in Q1 2011) were down 28%, reversing the gains that it had made in the first quarter. The decline in revenue was primarily caused by lower sales of what had been Bristol Myers Squibb’s leading product, Plavix, an antiplatelet drug which is designed to prevent heart attacks and strokes. Generic versions of Plavix came onto the market starting in May.

Wall Street analysts expect further decline in Bristol Myers Squibb Co.’s business, as the current stock price represents a trailing price-to-earnings ratio of 16 but a forward multiple of 18. The company also deserves mention as a defensive play and potential income stock as its beta of 0.2 demonstrates that it is almost immune to movements in the broader market and it pays a dividend yield of 4.1%.

RENAISSANCE TECHNOLOGIES

According to our database of 13F filings by hedge funds and other notable investors, the largest position in Bristol Myers Squibb Co. at the end of June belonged to Renaissance Technologies. Renaissance, a very successful hedge fund whose founder Jim Simons has become a billionaire, owned 13.3 million shares; this made it one of the fund’s top five holdings (see more of Renaissance’s favorite stocks). Adage Capital Management increased its stake by 28% to a total of 6 million shares (find more stock picks from Adage Capital Management). Samuel Isaly’s Orbimed Advisors, a healthcare-focused investor, also liked Bristol Myers Squibb as it was the fund’s second largest position at the end of June, with 5.1 million shares in its portfolio (research more stocks that Orbimed owned).

Bristol Myers Squibb is best compared to other large cap pharmaceutical companies such as AstraZeneca plc (NYSE:AZN), Merck & Co., Inc. (NYSE:MRK), Pfizer Inc. (NYSE:PFE), and Eli Lilly & Co. (NYSE:LLY). All four of these companies are cheaper than Bristol Myers Squibb on the basis of forward earnings estimates. AstraZeneca stands out when looking at these companies quantitatively, as it trades at 8 times consensus earnings for next year and in fact at 7 times trailing earnings. It also is not bad on the income front with a 3.9% dividend yield. However, its revenues and earnings were down 20-25% last quarter compared to a year earlier. Eli Lilly also saw double-digit percentage declines in these figures over the same period, and its dividend yield matches AstraZeneca’s. However, it is priced at a slight premium relative to that company at a forward P/E of 13.

Pfizer’s sales were down in its most recent quarter versus the same period last year, but its earnings were up 25%. The sell-side anticipates that the nearly $200 billion market cap company will grow its earnings over the next few quarters, and so it is priced at 19 times trailing earnings but only 11 times forward estimates. It’s not particularly a good value now, but is reasonably priced if it can meet its targets. Merck is in a similar situation: its trailing and forward P/Es are 21 and 12, respectively. Revenue was about flat last quarter versus a year earlier, but higher costs brought net income down. Between these two companies with similar valuation profiles, we’d prefer the one which has been experiencing earnings growth.

We don’t see any reason why Bristol Myers Squibb should be trading at such a premium to its peers. AstraZeneca is tempting based on its multiples, but we would need to check to make sure it can stabilize its business. Absent that, Pfizer looks to combine at least some earnings growth with a fairly low forward P/E.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The 10 Countries with the Highest Suicide Rates

The 10 Most Technologically Advanced Countries in the World

The 10 Safest Countries in the World to Live in Peace

The 10 Top Selling Smartphones in the World 2014

The 12 Biggest Shopping Centers in the World

The 10 Friendliest Countries in the World

Qihoo 360 Technology Co Ltd (QIHU), Actavis plc (ACT), Yahoo! Inc. (YHOO) Among 20 Long Ideas from Sohn Canada

The 10 Laziest Countries in the World

The 10 Most Polluted Countries in the World

The 10 Most Dangerous Cities in America 2014

The Top 10 Gold Producing Countries in the World

The 10 Tallest Buildings in the World

The 10 Richest Stand Up Comedians in the World

The 10 Fattest Countries in the World

The 5 Best Summer Jobs for Teens

The 10 Most Religious Countries in the World Keeping the Faith

The 10 Most Educated Countries in the World

The 10 Most Popular Cell Phones in the World

The 10 Drunkest Countries in the World

The 10 Most Expensive Private Schools in the World

The 10 Smallest Countries in the World

Walking Dead Season 5 Spoilers You’ll Wish You Didn’t Know

The 10 Poorest Countries in the World

The 10 Greenest Countries in the World

The Top 10 Countries with the Highest Population in the World

The 10 Most Visited Countries in the World

The Top 10 Star Wars Characters in the Iconic Series

The 10 Most Expensive Android Phones in the World

5 Reasons Why The Illuminati Is Real and a Threat to Society

The 6 Scariest Halloween Costumes Ever Screamed At

The 4 Biggest Hedge Fund Managers in the World Today

The 15 Most Densely Populated Countries in the World

The 10 Biggest Tea Drinking Countries in the World

Top 6 Ways to Improve Your Checkout Process and Close Sales

The 5 Most Profitable Online Businesses You Can Start Today

The 20 Most Profitable Hospitals in the US

The 5 Most Profitable Home Businesses to Start

The 7 Teams that Will Win the Stanley Cup in 2015

The Top 10 Most Expensive Digital Cameras to Snap Stunning Shots With

The 10 Highest Quality Fast Food Restaurants In America Today

The 8 Best Halloween Decorating Ideas to Spook Up Your House

10 Marvel Women that Should Get a Movie Right Now

The 20 Best Remixes of Popular Songs that Will Make You Forget the Originals

7 Most Expensive Cities in the World

5 Least Expensive Cities in the World

10 Celebrities Who Believe In Scientology

10 High Margin Food Products to Build a Business Around

The 10 Most Expensive Clothing Stores in the United States to Get Decked Out At

The 5 Biggest Kickstarter Scams That Swindled Backers’ Donations

The 10 Most Expensive Boarding Schools In the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!